Trial Profile
A Phase II Pilot Study to Determine the Safety and Preliminary Efficacy of Imatinib Mesylate (Gleevec) in Patients With Myelofibrosis With Myeloid Metaplasia.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2012
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 12 Jan 2012 Actual end date (1 Oct 2011) added as reported by ClinicalTrials.gov.
- 11 Oct 2011 Planned End Date changed from 1 Mar 2007 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 11 Oct 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.